Document is current

Article History

Accepted: 9 March 2023

First Online: 17 April 2023

Competing interests

: Alimentiv Inc. is an academic gastrointestinal contract research organization (CRO), operating under the Alimentiv Health Trust. Alimentiv Inc. provides comprehensive clinical trial services, precision medicine offerings, and centralized imaging solutions for endoscopy, histopathology, and other imaging modalities. The beneficiaries of the Alimentiv Health Trust are the employees of the enterprises it holds. None of the authors is a beneficiary of the Alimentiv Health Trust. B.V., N.V.C., G.D’H., B.G.F., V.J., C.M., W.J.S. and A.S. are consultants to Alimentiv Inc. and have a primary academic appointment; they do not hold equity positions or shares in Alimentiv Inc. B.V. reports research support from AbbVie, Biora Therapeutics, Pfizer, Sossei Heptares and Takeda; speaker’s fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and consultancy fees from Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Inotrem, Inotrem, Ipsos, Janssen, Mylan, Progenity, Sandoz, Sosei Heptares, Takeda Tillots Pharma and Viatris. A.S. reports research grants from Roche-Genentech, Abbvie, GSK, Scipher Medicine, Alimentiv Inc, Boehringer Ingelheim and Origo Biopharma; consulting fees from Genentech, GSK, Pfizer, HotSpot Therapeutics, Alimentiv, Origo Biopharma and Boxer Capital. B.E.S. reports research grants from Takeda, Pfizer, Theravance Biopharma R&D and Janssen; consulting fees from 4D Pharma, Abivax, Abbvie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Capella Bioscience, Celgene, Celltrion Healthcare, ClostraBio, Enthera, F.Hoffmann-La Roche, Ferring, Galapagos, Gilead, GlaxoSmithKline, GossamerBio, Immunic, Index Pharmaceuticals, Innovation Pharmaceuticals, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, MiroBio, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Rheos Medicines, Salix Pharmaceuticals, Seres Therapeutics, Shire, Sienna Biopharmaceuticals, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio, Vivante Health and Vivelix Pharmaceuticals; and holds stock in Vivante Health and Ventyx Biosciences. M.F.N. reports consulting fees from MSD Sharp & Dohme GmbH, PPM Services, IFM Therapeutics, Sterna Biologicals, Boehringer Ingleheim GmbH and Co. KG, Janssen Cilag GmbH, Pentax Europe GmbH, Takeda, Amgen GmbH, Pfizer Pharma, Falk Foundation e.v., Abbvie and Celgene. N.V.C. reports research grants and personal fees from R-Biopharm, Takeda and UCB; and personal fees from Alimentiv, Inc (formerly Robarts Clinical Trials, Inc), Celltrion and Prometheus. These activities were all outside the submitted work. C.A. and H.L. declare no competing interests. The competing interests of the Alimentiv Translational Research Consortium Member Authors are listed in Supplementary Box 1.